^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | gemcitabine (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
09/08/2020
Excerpt:
…NCCN Panel has included taxanes (paclitaxel), anthracyclines (doxorubicin and liposomal doxorubicin), anti-metabolites (capecitabine and gemcitabine), microtubule inhibitors (eribulin and vinorelbine), platinum agents for patients with triple negative tumors and germline BRCA 1/2 mutations.
Source:
Title:
Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer
Excerpt:
Multivariate analysis revealed that reaching a CR and PR (HR 0.17, 95%CI: 0.08–0.45, p < 0.001; HR 0.31, 95%CI: 0.12–0.79 and p 5 0.015) and having the BLBC subtype (HR 0.28, 95%CI: 0.13–0.62, p 5 0.002; HR 0.44, 95%CI: 0.19–1.00 and p 5 0.042) were independent favorable factors for PFS and OS, respectively. An interval from diagnosis to recurrence 1 year was an independent unfavorable factor for PFS (HR 1.70, 95%CI: 1.14–2.84 and p 5 0.045), but not OS (p > 0.05)...In conclusion, the GP combination is an effective and well-tolerated first-line chemotherapy regimen in patients with mTNBC.
